The effect of garlic supplements on the pharmacokinetics of saquinavir

被引:248
作者
Piscitelli, SC
Burstein, AH
Welden, N
Gallicano, KD
Falloon, J
机构
[1] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[2] NIAID, Dept Pharm, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA
[3] Axelson Biopharma Res, Vancouver, BC, Canada
关键词
D O I
10.1086/324351
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Herbal therapies are widely used, but there are few data on their interactions with conventional medications. This study evaluated the effect of garlic supplements on the pharmacokinetics of saquinavir. Ten healthy volunteers received 10 doses of saquinavir (Fortovase) at a dosage of 1200 mg 3 times daily with meals for 4 days on study days 1-4, 22-25, and 36-39, and they received a total of 41 doses of garlic caplets taken 2 times daily on study days 5-25. Blood samples were obtained on study days 4, 25, and 39 for determination of saquinavir plasma pharmacokinetic parameters. In the presence of garlic, the mean saquinavir area under the curve (AUC) during the 8-h dosing interval decreased by 51%, trough levels at 8 h after dosing decreased by 49%, and the mean maximum concentrations (C-max) decreased by 54%. After the 10-day washout period, the AUC, trough, and C-max values returned to 60%-70% of their values at baseline. Patients should use caution when combining garlic supplements with saquinavir when it is used as a sole protease inhibitor.
引用
收藏
页码:234 / 238
页数:5
相关论文
共 17 条
[1]  
[Anonymous], PHARM STAT PRACTICAL
[2]  
CHOUDHRI SH, 2000, 40 INT C ANT AG CHEM
[4]   Complementary AIDS therapies: The good, the bad and the ugly [J].
Ernst, E .
INTERNATIONAL JOURNAL OF STD & AIDS, 1997, 8 (05) :281-285
[5]   Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients [J].
Fairfield, KM ;
Eisenberg, DM ;
Davis, RB ;
Libman, H ;
Phillips, RS .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (20) :2257-2264
[6]  
Fitzsimmons ME, 1997, DRUG METAB DISPOS, V25, P256
[7]  
Foster BC, 2001, J PHARM PHARM SCI, V4, P176
[8]   Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients [J].
Gieschke, R ;
Fotteler, B ;
Buss, N ;
Steimer, JL .
CLINICAL PHARMACOKINETICS, 1999, 37 (01) :75-86
[9]   Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir [J].
Gisolf, EH ;
van Heeswijk, RPG ;
Hoetelmans, RWM ;
Danner, SA .
AIDS, 2000, 14 (07) :801-805
[10]  
Kim AE, 1998, J PHARMACOL EXP THER, V286, P1439